Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson's potential acquisition of Ollin Biosciences for up to $3.4 billion highlights the biotech sector's feverish activity in deal-making. This move by a major drugmaker underscores the growing importance of innovative eye disease treatments, which are becoming a significant focus for pharmaceutical companies. The acquisition could mean a major leap forward in addressing rare eye conditions, potentially offering new hope to patients worldwide and signaling a broader trend of consolidation in the biotech industry. For more details, check out the full article on Financial Times.
Original Source
Read the full article at Ft →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.